spacer
home > epc > spring 2018 > money matters
PUBLICATIONS
European Pharmaceutical Contractor

Money Matters

EPC: What are some of the challenges sites face when trying to be paid?

Dave Espenshade: A site’s ability to receive accurate and timely payments from sponsors or CROs is one of the most challenging processes it faces while conducting clinical trials. In fact, we often hear that payment terms are the biggest driver in a site’s ability to support a clinical study.

There are many reasons why this is such a challenge, with invoice adjudication being the biggest contributor to the limited transparency in the payment process. From a sponsor or CRO perspective, invoices are arriving in a variety of formats and often at different intervals. This causes a number of inconsistencies that their finance teams need to unravel to determine what work was performed, what rate was contracted, and what needs to be paid. This is a complex and difficult process, and, as a result, many sponsors and CROs pay their sites on a quarterly basis to keep up with this workload.

This time gap between services rendered and payment, along with the errors that often occur with payments, is one of the biggest challenges that sites face.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dave Espenshade is Vice President of CRO Partnerships at Greenphire. In his role, he leads the efforts to broaden the use of Greenphire’s solution suite among global CRO partners. Dave has more than two decades of experience in the software and life sciences industries and a demonstrated expertise in establishing successful partnerships between industryleading global CROs and software providers.
spacer
Dave Espenshade
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement